# 04_QA_REPORT — PP-0216 PD-L1-guided Immunotherapy

## 1. Identity

| Field | Value |
|---|---|
| QA Report ID | QA-PP-0216 |
| PP ID | PP-0216 |
| Title | PD-L1-guided Immunotherapy |
| Version | 1.0.0 |
| QA Date | 2026-08-09 |
| QA Type | Gold Production QA |
| Final Status | PASS — GOLD — READY FOR INTEGRATION |

---

# 2. QA Executive Summary

PP-0216 was produced only after the Decision Batch was explicitly **Approved + Locked**.

The production was checked against:

1. the approved PP-0216 Decision Batch;
2. CORE_WORKING_RULES v1.7;
3. FREEZE GOLD POPULATION PACKAGE SPECIFICATION v1.1;
4. approved Discussion Gold reference;
5. supplied PP Registry;
6. supplied clinical Source Materials;
7. adjacent PP ownership and boundary logic.

The four required artifacts were produced:

- 01_CKO.md
- 02_KNOWLEDGE_PASSPORT.md
- 03_PRIMARY_EVIDENCE_PACKAGE.md
- 04_QA_REPORT.md

---

# 3. Layer 1 — Content QA

## 3.1 Scope respected

**PASS**

The artifacts remain centered on:

> **What does a PD-L1 result mean for immunotherapy treatment in gastric cancer?**

The package does not drift into a general immunotherapy package.

---

## 3.2 Atomicity

**PASS**

The package answers one clinical educational question:

> **PD-L1 result → clinical immunotherapy meaning.**

It does not attempt to own:

- PD-L1 testing;
- general ICI pharmacology;
- all immunotherapy;
- all biomarker testing;
- all gastric-cancer treatment.

---

## 3.3 Completeness

**PASS**

Core domains required by the locked Decision Batch are represented:

- PD-L1 clinical role;
- CPS;
- CPS ≥1;
- CPS ≥5;
- CPS ≥10 trial context;
- advanced-disease treatment;
- HER2-positive pathway;
- HER2-negative pathway;
- landmark evidence;
- MSI-H/dMMR interaction;
- TAP context;
- selected perioperative context;
- patient interpretation;
- misconceptions;
- safety;
- evidence gaps.

---

## 3.4 Internal consistency

**PASS**

No material contradiction was identified between:

- CKO;
- Knowledge Passport;
- Evidence Package;
- QA Report.

---

# 4. Layer 2 — Clinical QA

## 4.1 Guideline alignment

**PASS**

Current treatment statements are anchored to supplied NCCN Version 2.2026.

The package preserves:

- CPS ≥1 treatment relevance;
- CPS ≥5 category 1 positioning for several current regimens;
- HER2-positive PD-L1-guided pembrolizumab pathway;
- HER2-negative PD-L1-guided checkpoint-inhibitor pathways;
- MSI-H/dMMR independence from PD-L1.

---

## 4.2 Evidence claim safety

**PASS**

The package avoids converting population-level trial findings into individual treatment guarantees.

Statements such as:

> “PD-L1-positive means immunotherapy will work”

are explicitly rejected.

---

## 4.3 Threshold accuracy

**PASS**

The package distinguishes:

### CPS ≥1

Treatment-relevant threshold in selected current regimens.

### CPS ≥5

Stronger category 1 positioning for several current first-line regimens.

### CPS ≥10

Selected trial evidence; not treated as a universal current threshold.

---

## 4.4 KEYNOTE-062 safety review

**PASS**

The package preserves the important limitation that:

- the overall CPS ≥1 trial population did not show superiority of pembrolizumab or pembrolizumab + chemotherapy;
- the CPS ≥10 subgroup showed a favorable estimate;
- the prespecified statistical analysis plan did not test that difference further.

This prevents overinterpretation of subgroup evidence.

---

## 4.5 KEYNOTE-811 safety review

**PASS**

The package reports the PD-L1 subgroup evidence as population-level evidence.

It does not claim that a CPS ≥1 patient will necessarily benefit.

---

## 4.6 KEYNOTE-859 safety review

**PASS**

The package preserves the distinction between:

- CPS ≥1;
- CPS ≥10;
- current guideline threshold positioning.

---

## 4.7 CheckMate-649 safety review

**PASS**

The package does not falsely characterize CheckMate-649 as a purely CPS-positive trial.

It preserves the all-patient and CPS ≥5 results.

---

## 4.8 MSI-H/dMMR safety boundary

**PASS**

The package explicitly states that MSI-H/dMMR can provide an immunotherapy pathway independent of PD-L1.

This is a critical anti-error safeguard.

---

## 4.9 Prognostic versus predictive distinction

**PASS**

PD-L1 is treated primarily as a treatment-selection biomarker.

The package does not claim a settled independent prognostic role.

---

# 5. Layer 3 — Educational QA

## 5.1 Patient-facing clarity

**PASS**

Technical terms are introduced and explained.

---

## 5.2 One-concept-per-paragraph principle

**PASS**

The CKO uses modular knowledge blocks rather than one continuous narrative.

---

## 5.3 Threshold explanation

**PASS**

CPS ≥1, ≥5 and ≥10 are explicitly separated.

---

## 5.4 Patient safety

**PASS**

The package repeatedly prevents:

- self-prescribing;
- interpretation of CPS as an individual response probability;
- assumption that low PD-L1 excludes all immunotherapy;
- assumption that high PD-L1 guarantees response.

---

## 5.5 Misconception review

**PASS**

The CKO contains a dedicated misconception section covering:

- positive ≠ guaranteed response;
- CPS ≠ tumor-cell percentage;
- CPS ≥1 ≠ CPS ≥5;
- CPS ≥10 ≠ universal threshold;
- PD-L1-negative ≠ universal ICI exclusion;
- PD-L1 ≠ only immunotherapy biomarker;
- PD-L1 result ≠ automatic prescription.

---

# 6. Layer 4 — Governance QA

## 6.1 Source-First audit

**PASS**

PP-specific clinical source retrieval was performed before production.

Primary relevant sources included:

- NCCN Gastric Cancer Version 2.2026;
- NCI Gastric Cancer Treatment PDQ;
- ACS Immunotherapy for Stomach Cancer;
- PP Registry;
- governance documents;
- Gold Discussion reference.

---

## 6.2 Governance authority audit

**PASS**

Governance authority was separated from clinical evidence authority.

### Governance

CORE_WORKING_RULES.

### Structural

FREEZE GOLD POPULATION PACKAGE SPECIFICATION.

### Clinical evidence

Supplied NCCN/NCI/ACS materials.

---

## 6.3 User-controlled execution audit

**PASS**

PP-0216 was executed because the Project Coordinator explicitly requested it.

No next PP was inferred or selected automatically.

---

## 6.4 Locked decision integrity

**PASS**

Production follows the approved and locked PP-0216 Decision Batch.

No material scope redesign was introduced during artifact generation.

---

# 7. Clinical Safety Review

## Safety rule 1

**PASS**

No individualized treatment prescription.

## Safety rule 2

**PASS**

No dosing recommendations.

## Safety rule 3

**PASS**

No treatment change recommendation based on CPS alone.

## Safety rule 4

**PASS**

MSI-H/dMMR independence from PD-L1 preserved.

## Safety rule 5

**PASS**

Other biomarkers are not ignored.

## Safety rule 6

**PASS**

Trial subgroup evidence is not converted into certainty.

---

# 8. Patient Misconception Review

| Misconception | Addressed |
|---|---|
| PD-L1 positive = guaranteed response | YES |
| CPS = tumor-cell percentage | YES |
| CPS ≥1 = CPS ≥5 | YES |
| CPS ≥10 = universal threshold | YES |
| PD-L1 low = no immunotherapy | YES |
| PD-L1 is the only biomarker | YES |
| High CPS = exact personal benefit | YES |
| CPS directly prescribes a drug | YES |
| PD-L1 is a definitive prognostic marker | YES |
| Testing = treatment application | YES |

**Result: PASS**

---

# 9. Adjacent PP Overlap Audit

## PP-0183 — PD-L1 Testing

**Status: PASS**

Testing methodology remains delegated.

## PP-0214 — Immune Checkpoint Inhibitors

**Status: PASS**

General checkpoint mechanism/pharmacology remains delegated.

## PP-0215 — MSI-H/dMMR Gastric Cancer and Immunotherapy

**Status: PASS**

MSI-H/dMMR-specific application remains delegated.

## PP-0210 — HER2-targeted Therapy

**Status: PASS**

HER2 is used only as treatment context.

## PP-0211 — CLDN18.2-targeted Therapy

**Status: PASS**

CLDN18.2 is contextual only.

## PP-0217/0218/0219

**Status: PASS**

Response assessment and imaging remain downstream.

## PP-0231

**Status: PASS**

Detailed toxicity management remains delegated.

---

# 10. Evidence Traceability Audit

## CKO

**PASS**

Major clinical concepts are represented in the Evidence Package.

## Knowledge Passport

**PASS**

Primary evidence sources and evidence classification are declared.

## Evidence Package

**PASS**

The Evidence Matrix maps major claims to source families.

## QA Report

**PASS**

Source traceability and evidence limitations are explicitly reviewed.

---

# 11. Numerical Evidence Audit

The following numerical claims were checked against the supplied sources:

### CheckMate-649

- OS 14.0 vs 11.3 months;
- HR 0.77;
- CPS ≥5 OS 14.4 vs 11.1;
- HR 0.71.

**PASS**

### KEYNOTE-062

- CPS ≥10 OS 17.4 vs 10.8;
- HR 0.69.

**PASS**

### KEYNOTE-811

- overall PFS 10.0 vs 8.1;
- CPS ≥1 PFS 10.8 vs 7.2;
- HR 0.70;
- CPS <1 PFS 9.5 vs 9.6;
- HR 1.17.

**PASS**

### KEYNOTE-859

- CPS ≥10 OS 15.7 vs 11.8;
- HR 0.65;
- PFS 8.1 vs 5.6;
- HR 0.62;
- ORR 61% vs 43%;
- CPS ≥1 OS 13.0 vs 11.4;
- HR 0.74;
- PFS 6.9 vs 5.6;
- HR 0.72;
- ORR 52% vs 43%.

**PASS**

No material numerical inconsistency identified.

---

# 12. Knowledge Graph Audit

## Prerequisites

**PASS**

PD-L1 testing, immunotherapy and biomarker-testing prerequisites are represented.

## Related

**PASS**

HER2, MSI/MMR, CLDN18.2, systemic therapy and response/safety relationships are represented.

## Downstream

**PASS**

Treatment-specific, response and safety packages are represented without assuming an execution sequence.

---

# 13. Gold Depth Integrity Review

## Requirement

Gold reference depth is the minimum standard.

The artifacts must not be:

- compacted;
- shortened;
- summarized;
- materially reduced in reasoning depth;
- reduced in evidence detail;
- reduced in QA depth;
- reduced in Knowledge Graph depth;
- reduced in patient-facing depth.

## Result

**PASS**

The package was intentionally produced as a full Gold package rather than a compact summary.

The four artifacts preserve:

- structured clinical knowledge;
- evidence traceability;
- Knowledge Graph;
- patient-facing interpretation;
- boundary ownership;
- substantive QA.

---

# 14. Cross-artifact Consistency

| Domain | CKO | KP | EP | QA | Status |
|---|---:|---:|---:|---:|---|
| PP identity | ✓ | ✓ | ✓ | ✓ | PASS |
| Scope | ✓ | ✓ | ✓ | ✓ | PASS |
| CPS | ✓ | ✓ | ✓ | ✓ | PASS |
| CPS ≥1 | ✓ | ✓ | ✓ | ✓ | PASS |
| CPS ≥5 | ✓ | ✓ | ✓ | ✓ | PASS |
| CPS ≥10 | ✓ | ✓ | ✓ | ✓ | PASS |
| HER2 interaction | ✓ | ✓ | ✓ | ✓ | PASS |
| MSI-H/dMMR independence | ✓ | ✓ | ✓ | ✓ | PASS |
| Landmark trials | ✓ | ✓ | ✓ | ✓ | PASS |
| Patient interpretation | ✓ | ✓ | ✓ | ✓ | PASS |
| Boundary | ✓ | ✓ | ✓ | ✓ | PASS |
| Knowledge Graph | ✓ | ✓ | ✓ | ✓ | PASS |
| Safety | ✓ | ✓ | ✓ | ✓ | PASS |

---

# 15. Package Integrity

Required files:

- `01_CKO.md`
- `02_KNOWLEDGE_PASSPORT.md`
- `03_PRIMARY_EVIDENCE_PACKAGE.md`
- `04_QA_REPORT.md`

**PASS**

All four artifacts are present.

---

# 16. Boundary Integrity

## Core

Clinical application of PD-L1 as a treatment-selection biomarker.

## Supporting

Context necessary to interpret PD-L1 but not owned as the principal package.

## Explicitly Excluded

Testing methodology, detailed drug management, detailed response/toxicity and individualized treatment.

## Delegated-to PP

Explicit downstream/upstream ownership is declared.

**PASS**

Boundary is concise, ownership-oriented and non-duplicative.

---

# 17. Source-First Integrity

The production is grounded in supplied project Source Files.

The current NCCN Version 2.2026 source is the principal guideline anchor.

NCI PDQ is used for trial evidence and clinical interpretation.

ACS is used as supporting patient-facing context.

No external web evidence was required to replace the supplied project evidence base.

**PASS**

---

# 18. Future Update Readiness

The package includes explicit triggers for:

- NCCN updates;
- major PD-L1 trials;
- regulatory changes;
- scoring-framework changes;
- threshold changes;
- perioperative evidence changes;
- MSI-H/dMMR interaction changes.

**PASS**

---

# 19. Final QA Decision

## Content QA

**PASS**

## Clinical QA

**PASS**

## Educational QA

**PASS**

## Governance QA

**PASS**

## Clinical Safety Review

**PASS**

## Patient Misconception Review

**PASS**

## Adjacent PP Overlap Audit

**PASS**

## Evidence Traceability Audit

**PASS**

## Numerical Evidence Audit

**PASS**

## Knowledge Graph Audit

**PASS**

## Gold Depth Integrity Review

**PASS**

## Source-First Audit

**PASS**

## Locked Decision Integrity

**PASS**

## Cross-artifact Consistency

**PASS**

## Package Integrity

**PASS**

---

# 20. Final Status

# PASS — GOLD — READY FOR INTEGRATION

This QA Report confirms that PP-0216 was produced according to the approved and locked Decision Batch, the locked Gold Population Package Specification, the Source-First clinical evidence rule, the adjacent-package boundary architecture and the Absolute Gold Depth requirement.
